RE:RE:RE:ONCY's pelareorep is now Phase 3-readyDr. Piccart also commented on pelareorep + paclitaxel's combination scoring high on the ESMO - Magnitude of Clinical Benefit Scale.
https://www.esmo.org/guidelines/esmo-mcbs/about-the-esmo-mcbs ESMO-MCBS was developed in 2015 as a validated and reproducible scale that is applicable across the full range of solid tumours and since 2023 in hematological malignancies. The latter has been developed in collaboration with the European Haematological Association (EHA).
It incorporates a structured, rational and valid approach to clinical trial data interpretation and analysis that reduces the tendency to have judgements affected by bias or uninformed and/or idiosyncratic data interpretation that has been developed in accordance with the ethical framework for fair decision-making and public policy standard of “accountability for reasonableness